Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €135.20 EUR
Change Today +0.70 / 0.52%
Volume 1.1K
BAY On Other Exchanges
Symbol
Exchange
BrsaItaliana
Xetra
Mexico
Continuous
As of 6:44 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-reg (BAY) Snapshot

Open
€134.70
Previous Close
€134.50
Day High
€135.30
Day Low
€134.70
52 Week High
03/18/15 - €148.20
52 Week Low
08/8/14 - €94.40
Market Cap
111.8B
Average Volume 10 Days
2.4K
EPS TTM
--
Shares Outstanding
826.9M
EX-Date
05/28/15
P/E TM
--
Dividend
€2.25
Dividend Yield
1.66%
Current Stock Chart for BAYER AG-REG (BAY)

bayer ag-reg (BAY) Related Bloomberg News

View More Bloomberg News

bayer ag-reg (BAY) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as anticoagulants; medicines to treat hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary hypertension, high blood pressure, and infectious diseases; and contraceptives, as well as provides consumer health products, including over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; and contrast agent injection systems for diagnostic and therapeutic medical procedures in X-ray, computed tomography, and magnetic resonance imaging. The CropScience segment offers products in the areas of seeds and plant traits, and crop protection; and products for use in gardens and non-agricultural pest control, as well as green industry. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and specialty chemicals; and selected inorganic basic chemicals. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

117,798 Employees
Last Reported Date: 07/29/15
Founded in 1863

bayer ag-reg (BAY) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €520.0K
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €2.0M
Labor Director and Member of Management Board
Total Annual Compensation: €1.6M
Member of Management Board, Chief Medical Off...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

bayer ag-reg (BAY) Key Developments

Bayer AG Announces Group Earnings Results for the Second Quarter of 2015; Confirms Earnings Guidance for 2015; Provides Earnings Guidance for the Remainder of the Year 2015

Bayer AG announced Group earnings results for the second quarter of 2015. Group sales climbed by 4% organically to EUR 12.1 billion, supported mainly by its HealthCare business. Reported EBIT came in 28% ahead of the prior year's quarter after net special charges of EUR 255 million, mainly comprised of integration costs, expenses for the planned stock market flotation of MaterialScience, efficiency improvements and measures to improve its production structures. Adjusted EBITDA for the group posted an increase of 33% to EUR 2.9 billion, driven by the positive business development. And then core earnings per share amounted to EUR 1.98, an increase of 34% over the prior year. As a result of the improvement in EBITDA, gross cash flow advanced 31% in the quarter. Net cash flow rose by 24% to EUR 2.0 billion, despite more funds having been tied up in working capital versus the prior year. With capital expenditures of EUR 600 million, the operating free cash flow came in at roughly EUR 1,350,000,000. The company provided earnings guidance for the remainder of the year 2015. Based on its performance in the first half, its expectations for the remainder of the year and using end-of second quarter exchange rates its guidance for sales from continuing operations in the region of EUR 47 billion. Its previous guidance was in the region of EUR 48 billion to EUR 49 billion included discontinued operations of Diabetes Care of approximately EUR 900 million. This level corresponds to a low single-digit percentage increase of its revenue on a currency- and portfolio-adjusted basis. For adjusted EBITDA, it remains its goal to increase in the high-teens percentage.

Bayer AG Plans To List Plastics Divisions By October

Bayer AG (DB:BAYN) is planning to list its plastics division by October 2015, according to sources familiar with the deal. Bayer AG will decide the exact time of the offering just days ahead of the actual launch of the initial public offering. According to sources, Bayer wants to complete the preparations by August 2015. A Bayer spokesman reiterated previous statements that the plastics division would become a separately listed company by mid-2016 at the latest.

Monsanto Says Bayer Among Options If Syngenta Deal Fails

Monsanto Company (NYSE:MON) is exploring other options should Syngenta AG (SWX:SYNN) should continue to reject the deal. Monsanto would approach Bayer AG (DB:BAYN) about acquiring its crop chemicals business if it can’t buy Syngenta, Brett Begemann Chief Operating Officer of Monsanto said. While Monsanto is “committed” to acquiring Syngenta, “we won’t stay at it forever,” he said. “There are other options to pursue from a chemical standpoint, and we will go after those,” Begemann said. “I don’t know what Bayer is going to do with their crop-protection business, whether they’ll sell it or not, but I’m sure they’d be happy to talk about some other kind of marketing arrangement.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAY:IM €135.20 EUR +0.70

BAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $69.73 USD -0.28
Allergan plc $334.92 USD +3.77
GlaxoSmithKline PLC 1,407 GBp +6.50
Novo Nordisk A/S kr408.20 DKK -1.30
Sanofi €98.12 EUR -0.52
View Industry Companies
 

Industry Analysis

BAY

Industry Average

Valuation BAY Industry Range
Price/Earnings 31.3x
Price/Sales 2.4x
Price/Book 4.9x
Price/Cash Flow 31.3x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-REG, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.